CD274 and neoplasm: In the HARMONi-5 trial (NCT04900363) involving immunotherapy-naive advanced NSCLC patients, ivonescimab achieved an ORR of 39.8% and a DCR of 86.1%, with efficacy correlating to PD-L1 expression levels: ORRs were 14.7% (tumor proportion score [TPS] <1%), 51.4% (TPS ≥1%), and 57.1% (TPS ≥50%).128